Orphazyme's fate sealed as creditors approve Kempharm sale
On Monday, the biotech firm’s creditors have adopted a proposed restructuring plan, clearing the way forward to selling Orphazyme’s activities to US-based Kempharm.
by christopher due karlsson, translated by daniel pedersen
Creditors of Orphazyme, a publicly listed biotech firm in Denmark, have accepted the restructuring plans that would see the firm sold off to US-based Kempharm, the Danish company has announced in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg)
.jpg)
.jpg)
.jpg&w=384&q=75)
